Clinical trials: Posterior Fossa Tumor, active
Posterior Fossa Lesion
Comparison of Surgical Outcomes of Craniotomy and Craniectomy in Posterior Fossa Lesions
The purpose of this randomized controlled trial is to compare the surgical outcomes of craniotomy and craniectomy among patients with posterior fossa lesions.
- Trial name
- NCT06831695
- Testing
- Craniotomy, Craniectomy
- Volunteers
- 80 people
- Sponsor
- University of Health Sciences Lahore
Medulloblastoma
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
- Trial name
- NCT05535166
- Testing
- Surgical resection, Ommaya/VPS, Methotrexate
- Where
- 10 sites in United States
- Volunteers
- 130 people
- Sponsor
- St. Jude Children's Research Hospital
Intracranial Pressure Increase
Posterior Fossa Intracranial Pressure (ICP) Measurement: Clinical Study
In modern medicine, doctors attempt to monitor all physiological variables to assess their evolution and to decide, based on their changes, the therapeutic attitudes to adopt.
- Trial name
- Postfossa ICP (NCT04675216)
- Testing
- Posterior fossa intracranial pressure measurement
- Where
- 2 sites in Spain
- Volunteers
- 12 people
- Sponsor
- University of Valencia
Glioblastoma, Medulloblastoma
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Indoximod was developed to inhibit the IDO (indoleamine 2,3-dioxygenase) enzymatic pathway, which is important in the natural regulation of immune responses.
- Conditions
- Glioblastoma, Medulloblastoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
- Trial name
- NCT04049669
- Testing
- Indoximod, Partial Radiation, Full-dose Radiation
- Where
- 5 sites in United States
- Volunteers
- 130 people
- Sponsor
- Theodore S. Johnson
Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
The purpose of this study is to assess the feasibility, safety and efficacy of H3K27M-specific engineered immune effector (EIE) therapy in patients with high-risk, H3K27M-positive diffuse midline glioma/diffuse intrinsic pontine…
- Trial name
- NCT07501156
- Testing
- H3K27M-EIEs
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Pilomyxoid Astrocytoma, Pilocytic Astrocytoma
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
This is a study to determine the safety and efficacy of the drug, mebendazole, when used in combination with standard chemotherapy drugs for the treatment of pediatric brain tumors.
- Conditions
- Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Glioma, Astrocytic, Optic Nerve Glioma
- Trial name
- NCT01837862
- Testing
- Mebendazole, Vincristine, Carboplatin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Julie Krystal
Diffuse Intrinsic Pontine Glioma, Brainstem Glioma
Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma
The purpose of this study is to prospectively collect specimens from pediatric patients with diffuse intrinsic pontine glioma or brainstem glioma, either during therapy or at autopsy, in order to characterize the molecular…
- Trial name
- NCT01106794
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Children's National Research Institute
High-grade Glioma, Medulloblastoma
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
The goal of this interventional study is to Assess the safety and tolerability of atovaquone in combination with standard radiation therapy (RT) for the treatment of pediatric patients with newly diagnosed pediatric high-grade…
- Conditions
- High-grade Glioma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
- Trial name
- AflacBT2303 (NCT06624371)
- Testing
- Atovaquone, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Emory University
Malignant Glioma, Ependymoma
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
This is a multicenter trial of the Optune device to examine the feasibility and to describe the device-related toxicity in children with supratentorial high grade glioma (HGG) or ependymoma (Stratum 1) and to examine the…
- Conditions
- Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
- Trial name
- NCT03033992
- Testing
- Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Concurrent Optune and RT followed by Optune System alone
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Children's Oncology Group
Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma
RE-irradiation of Diffuse MIdline Glioma paTients
The REMIT (RE-irradiation of diffuse MIdline glioma paTients) study evaluates safety and the palliative efficacy of re-irradiation of patients with diffuse midline glioma (DMG).
- Conditions
- Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma, Diffuse Glioma, Pontine Tumors
- Trial name
- REMIT (NCT06093165)
- Testing
- Re-irradiation
- Volunteers
- 59 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Combination Therapy for the Treatment of Diffuse Midline Gliomas
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs).
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant
- Trial name
- PNOC022 (NCT05009992)
- Testing
- ONC201, Radiation Therapy, Paxalisib
- Where
- 32 sites in United States, Australia and 4 more
- Volunteers
- 360 people
- Sponsor
- University of California, San Francisco
GBM, DIPG Brain Tumor
Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma
Primary brain malignant tumor has become the first lethal tumor in children and young adults, and the treatment is limited, and the prognosis of patients is poor.
- Conditions
- GBM, DIPG Brain Tumor, Medulloblastoma
- Trial name
- CSAγδTBMG (NCT06396481)
- Testing
- Vγ9Vδ2 T cell
- Where
- China
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
This phase I trial studies the side effects and best dose of pembrolizumab and to see how well it works in treating younger patients with high-grade gliomas (brain tumors that are generally expected to be fast growing and…
- Conditions
- Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome, Malignant Glioma, Recurrent Brain Neoplasm
- Trial name
- NCT02359565
- Testing
- Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging
- Where
- 12 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- National Cancer Institute (NCI)
High Grade Glioma (HGG) of the Brain With BRAF Aberration, High Grade Glioma (III or IV)
Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)
The goal of this study is to determine the efficacy of the study drugs tovorafenib to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways…
- Conditions
- High Grade Glioma (HGG) of the Brain With BRAF Aberration, High Grade Glioma (III or IV), Diffuse Intrinsic Pontine Glioma, High Grade Glioma
- Trial name
- NCT07206849
- Testing
- Tovorafenib
- Volunteers
- 79 people
- Sponsor
- Nationwide Children's Hospital
Medulloblastoma
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Historically, medulloblastoma treatment has been determined by the amount of leftover disease present after surgery, also known as clinical risk (standard vs. high risk).
- Trial name
- NCT01878617
- Testing
- Craniospinal Irradiation with boost to the primary tumor site, Cyclophosphamide, Cisplatin
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 660 people
- Sponsor
- St. Jude Children's Research Hospital
Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma, High Grade Gliomas
NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors
This is an open-label phase 1 safety and feasibility study evaluating a novel combination therapy for progressive and relapsed diffuse midline glioma (DMG) and other progressive and relapsed high-grade brain tumors.
- Conditions
- Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma, High Grade Gliomas, Medulloblastoma Recurrent, Ependymoma Recurrent
- Trial name
- NCT07664176
- Testing
- NeuroNavigation-Guided Focused Ultrasound (NgFUS), Lumason, Nivolumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Children's National Research Institute
Melanoma, Hodgkin Lymphoma
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors.
- Conditions
- Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM)
- Trial name
- NCT06521567
- Testing
- Cobolimab, Dostarlimab
- Where
- 20 sites in United States, Czechia and 4 more
- Volunteers
- 83 people
- Sponsor
- GlaxoSmithKline
Diffuse Intrinsic Pontine Gliomas (DIPG)
IMPT Versus IMRT for Diffuse Intrinsic Pontine Glioma
This is a prospective, open-label, multicenter, phase III randomized controlled trial comparing intensity-modulated proton therapy (IMPT) with intensity-modulated radiation therapy (IMRT) in participants aged 3-18 years with…
- Trial name
- NCT07869524
- Testing
- Intensity-Modulated Proton Therapy (IMPT), Intensity-Modulated Radiation Therapy (IMRT)
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Shandong Cancer Hospital and Institute
Oncology, DIPG
xPedite: A Study to Expedite DIPG and DMG Research
This study will gather data from new and existing patients with patient medical records, and patient/family/caregiver reported information to establish a clear natural history of disease suitable to serve as an external…
- Conditions
- Oncology, DIPG, DMG
- Trial name
- NCT06140719
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- xCures
Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3-specific chimeric antigen receptor (CAR) and EGFRt.
- Conditions
- Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Ependymoma
- Trial name
- NCT04185038
- Testing
- SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Seattle Children's Hospital